Cognition Therapeutics, Inc.
CGTX
$1.01
-$0.03-2.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.77% | -9.77% | -1.75% | -15.27% | -19.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.64% | -35.99% | 27.49% | -55.92% | -4.77% |
| Operating Income | 44.64% | 35.99% | -27.49% | 55.92% | 4.77% |
| Income Before Tax | 41.61% | 46.11% | 57.37% | 50.39% | 4.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 41.61% | 46.11% | 57.37% | 50.39% | 4.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.61% | 46.11% | 57.37% | 50.39% | 4.36% |
| EBIT | 44.64% | 35.99% | -27.49% | 55.92% | 4.77% |
| EBITDA | 44.65% | 35.95% | -27.68% | 55.94% | 4.71% |
| EPS Basic | 58.94% | 62.68% | 78.52% | 74.30% | 39.84% |
| Normalized Basic EPS | 59.00% | 62.66% | 79.00% | 74.30% | 39.80% |
| EPS Diluted | 60.55% | 63.43% | 78.65% | 74.72% | 38.89% |
| Normalized Diluted EPS | 59.00% | 62.66% | 79.00% | 74.30% | 39.80% |
| Average Basic Shares Outstanding | 42.29% | 44.26% | 98.31% | 92.86% | 58.98% |
| Average Diluted Shares Outstanding | 42.29% | 44.26% | 98.31% | 92.86% | 58.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |